文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

德拉马尼还是普托马尼?所罗门式的判断!

Delamanid or pretomanid? A Solomonic judgement!
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

为缩小德拉马尼与普托马尼比较认识的差距,本文总结二者临床前研究主要发现,涵盖化合物鉴定、作用机制、耐药、体外活性、体内药代动力学及临床前体内活性与疗效,指出二者虽相似但存在差异,部分结核分枝杆菌分离株对其一耐药而对另一保留敏感性,体外和临床前体内活性显示德拉马尼在较低浓度和剂量下MIC更低、分枝杆菌载量下降更高,但在暴露等效于当前获批临床剂量的体内临床前杀菌活性比较时差异消失。

要点

  • 部分结核分枝杆菌分离株对德拉马尼或普托马尼之一耐药,但对另一化合物保留敏感性。
  • 基于体外和临床前体内活性,德拉马尼在较低药物浓度和剂量下MIC更低、分枝杆菌载量下降更高。
  • 在暴露等效于当前获批临床剂量的体内临床前杀菌活性比较中,两化合物活性差异消失。

核心结论

  • 德拉马尼与普托马尼同属硝基咪唑类,临床前研究显示二者有许多相似之处,但也存在若干差异。
  • 部分结核分枝杆菌分离株对德拉马尼或普托马尼之一耐药而对另一保留敏感性,可能意味着二者可在某些方案中互相替代。
  • 基于体外和临床前体内活性,德拉马尼在较低药物浓度和剂量下MIC更低、分枝杆菌载量下降更高;但在暴露等效于当前获批临床剂量的体内临床前杀菌活性比较中,该差异消失。
  • 鉴于临床前体外和体内模型固有的变异性,解读这些比较结果需谨慎。

研究设计与样本

  • 本文为临床前研究综述,总结德拉马尼与普托马尼的化合物鉴定、作用机制、耐药、体外活性、体内药代动力学及临床前体内活性与疗效。

主要发现

  • 部分结核分枝杆菌分离株对德拉马尼或普托马尼之一耐药,但对另一化合物保留敏感性。
  • 基于体外和临床前体内活性,德拉马尼在较低药物浓度和剂量下MIC更低、分枝杆菌载量下降更高。
  • 在暴露等效于当前获批临床剂量的体内临床前杀菌活性比较中,两化合物活性差异消失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 临床前体外和体内模型存在固有变异性,解读比较结果需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are urgently needed. The landscape of TB treatment has changed considerably over the last decade with the approval of three new compounds: bedaquiline, delamanid and pretomanid. Of these, delamanid and pretomanid belong to the same class of drugs, the nitroimidazoles. In order to close the knowledge gap on how delamanid and pretomanid compare with each other, we summarize the main findings from preclinical research on these two compounds. We discuss the compound identification, mechanism of action, drug resistance, in vitro activity, in vivo pharmacokinetic profiles, and preclinical in vivo activity and efficacy. Although delamanid and pretomanid share many similarities, several differences could be identified. One finding of particular interest is that certain Mycobacterium tuberculosis isolates have been described that are resistant to either delamanid or pretomanid, but with preserved susceptibility to the other compound. This might imply that delamanid and pretomanid could replace one another in certain regimens. Regarding bactericidal activity, based on in vitro and preclinical in vivo activity, delamanid has lower MICs and higher mycobacterial load reductions at lower drug concentrations and doses compared with pretomanid. However, when comparing in vivo preclinical bactericidal activity at dose levels equivalent to currently approved clinical doses based on drug exposure, this difference in activity between the two compounds fades. However, it is important to interpret these comparative results with caution knowing the variability inherent in preclinical in vitro and in vivo models.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mudde SE, Upton AM, Lenaerts A, et al. Delamanid or pretomanid? A Solomonic judgement! J Antimicrob Chemother. 2022. PMID: 35089314. doi:10.1093/jac/dkab505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。